For research use only. Not for therapeutic Use.
Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
At the endpoint, the protein production of MIP-1β, MCP-1, IL-6, and IL-10 in the colon tissues decrease in concordance with the plasma concentrations of the cytokines. The drug-treated groups reveal lower expression of p-STAT3 compared to the CAC group. In addition, BCL2 decreases and BAX increases markedly in the BSZ+VSL#3 group[1]. Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug[2].
| Catalog Number | I004936 |
| CAS Number | 80573-04-2 |
| Synonyms | 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid |
| Molecular Formula | C17H15N3O6 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26) |
| InChIKey | IPOKCKJONYRRHP-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O |
| Reference | [1]. Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61. [2]. Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789. |
